Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in body’s immune system to control inflammation. Recent studies have suggested potential link between their use and an increased risk nephrolithiasis. We conducted study further investigate this association. Methods: The used multiple logistic regression analysis assess association biologic A p-value <0.05 was considered statistically significant. SAS 9.4 for statistical analysis. Results: final sample consisted 22,895 cases, among which 5603 (24.51%) were receiving at least one drug. received as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); Golimumab, 121 (0.53%). There 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) treatment. found that (OR = 1.307, 95% CI 1.076–1.588, p 0.0071) odds Nephrolithiasis by 31%. Conclusion: associated two or more also compared no